Regardless of the presence or absence of DCs, this nanovaccine activated tumor-specific CD8 T cells, exhibiting more effective induction of tumor-specific CD8 T-cell responses and exhibiting high antitumor efficacy in tumor-bearing mice (50). The gene discussed is CD8A; the disease is neoplasm.